Follistatin-344
Overview
Follistatin-344 is a 344-amino acid glycoprotein that functions as a binding protein and endogenous antagonist of myostatin and other members of the TGF-beta superfamily. By sequestering myostatin, follistatin removes inhibitory signals that limit skeletal muscle growth, thereby permitting increased muscle fiber hypertrophy and hyperplasia. The peptide also modulates activin and bone morphogenetic protein signaling pathways.
Key Research Findings
Preclinical studies in animal models have demonstrated substantial increases in muscle mass following follistatin gene delivery or protein administration. Human clinical investigation has been extremely limited, with no controlled trials published as of current literature review. Safety concerns regarding off-target effects on reproductive and metabolic pathways remain unaddressed.
Intramuscular injection, Gene delivery
Research Phase
Interested in Follistatin-344?
Find a verified provider experienced with Follistatin-344 protocols in your area. All providers are credentialed and use compliant sourcing.
Find a Follistatin-344 ProviderRelated Peptides
Melanotan II
Research PhaseA synthetic cyclic analog of alpha-melanocyte stimulating hormone (alpha-MSH) that non-selectively activates melanocortin receptors MC1R through MC5R. Melanotan II stimulates melanogenesis for skin tanning via MC1R, modulates sexual arousal through MC3R/MC4R in the hypothalamus, and reduces appetite through central MC4R activation. It is not FDA-approved and carries significant safety concerns.
IGF-1 LR3 (Long-Arg3)
Research PhaseIGF-1 LR3 is a synthetic analogue of insulin-like growth factor 1 with an N-terminal extension of 13 amino acids and a substitution of arginine for glutamic acid at position 3. These modifications reduce binding to IGF-binding proteins, resulting in an extended half-life and increased bioavailability compared to native IGF-1. The peptide promotes anabolic processes including muscle protein synthesis, glucose uptake, and cellular proliferation. IGF-1 LR3 is not approved for human use and is primarily available as a research reagent, though it is sometimes misused in athletic and bodybuilding contexts.
IGF-1 DES (1-3)
Research PhaseIGF-1 DES (1-3) is a truncated analogue of insulin-like growth factor 1 lacking the first three N-terminal amino acids (glycine-proline-glutamate). This structural modification prevents binding to IGF binding proteins in serum, resulting in a shorter half-life but significantly increased potency at the IGF-1 receptor compared to native IGF-1. The peptide is hypothesized to promote localized muscle hypertrophy and tissue repair through enhanced receptor activation in target tissues.
MGF (Mechano Growth Factor)
Research PhaseMechano Growth Factor is a splice variant of the IGF-1 gene expressed in response to mechanical stress on muscle tissue. The peptide contains a unique C-terminal domain resulting from alternative splicing that distinguishes it from systemic IGF-1. MGF is proposed to act locally in skeletal muscle to activate satellite cells and promote muscle fiber repair and hypertrophy following mechanical loading or injury.